Efficacy of empagliflozin as adjunctive therapy to citalopram in major depressive disorder: a randomized double-blind, placebo-controlled clinical trial

Atefeh Zandifar,Maryam Panahi,Rahim Badrfam,Mostafa Qorbani

DOI: https://doi.org/10.1186/s12888-024-05627-0

IF: 4.144

2024-02-27

BMC Psychiatry

Abstract:Major depressive disorder is one of the most common psychiatric disorders, which is associated with a high disease burden. Current treatments using antidepressants have limitations, so using medication with neuromodulating and anti-inflammatory properties alongside them could be helpful. In a clinical trial, we studied the effectiveness of empagliflozin, a blood sugar-lowering drug, as an adjunctive therapy to reduce the severity of depression symptoms.

psychiatry